Talk:Moxonidine
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Moxonidine.
|
In what long-term CT moxonidine was proved to reduce mortality?
"Excess mortality has been seen in patients with symptomatic heart failure in the MOXCON study. However, the MOXCON trial utilised a very high dose of 3.0 mg daily which is well above the normal dose of 0.2–0.6 mg daily."
There is an inaccuracy here. The original article describes a different, significantly lower dosage than indicated in the Wikipedia article (at least two times less, 1 and 1.5 mg were the maximum doses, they were not prescribed to all the patients, but not 3 mg, as the author of the Wikipedia article points out): "Moxonidine SR or matching placebo was initiated at a dose of 0.25 mg BID, which could be increased at 1–2 week intervals to doses of 0.5, 1.0 and 1.5 mg BID".
In what long-term CT moxonidine was proved to reduce mortality? I haven't found any such CT, maybe just because they don't exist? If anyone knows such CT, please share the link. So far, there are only CT, where moxonidine is shown to increase mortality. 176.59.164.4 (talk) 17:33, 10 June 2022 (UTC)